Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses multiparametric assays in breast cancer.
Peter Voorhees, MD, physician, Levine Cancer Institute, discusses treatments for patients with relapsed multiple myeloma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.
John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the prognosis of patients with chronic lymphocytic leukemia.
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the potential benefit of using biosimilars in the treatment of patients with breast cancer.
Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.
Michael Rosenzweig, MD, assistant professor in the department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses emerging agents in the treatment of patients with amyloidosis.
Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.
Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.
Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).
Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in high-risk patients with chronic lymphocytic leukemia (CLL).
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.
David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.
Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the impact of minimal residual disease (MRD) on clinical practice.
Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.
Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.
Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.
Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.
Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.
Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.
Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the approval process for biosimilars.
Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the treatment of pediatric patients with high-risk neuroblastoma.
Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.
Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.
Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.
Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the WINS and WHEL trials in patients with breast cancer.
